Vera Therapeutics Inc. (VERA) Performance and Fundamentals Dashboard tells a completely different story

Vera Therapeutics Inc. (NASDAQ: VERA) stock jumped 5.15% on Friday to $8.99 against a previous-day closing price of $8.55. With 0.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.00 whereas the lowest price it dropped to was $8.22. The 52-week range on VERA shows that it touched its highest point at $24.98 and its lowest point at $5.20 during that stretch. It currently has a 1-year price target of $29.14.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VERA was up-trending over the past week, with a rise of 49.34%, but this was down by -51.95% over a month. Three-month performance dropped to -51.54% while six-month performance fell -45.12%. The stock lost -54.71% in the past year, while it has lost -53.54% so far this year. A look at the trailing 12-month EPS for VERA yields -2.95 with Next year EPS estimates of -3.19. For the next quarter, that number is -0.90. This implies an EPS growth rate of 41.20% for this year and -2.20% for next year.

Float and Shares Shorts:

At present, 27.22 million VERA shares are outstanding with a float of 25.24 million shares on hand for trading. In addition to Dr. Marshall Fordyce M.D. as the firm’s Founder, Pres, CEO & Director, Mr. Sean P. Grant M.B.A. serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 92.20% of VERA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 33.43% of VERA, in contrast to 23.44% held by mutual funds. Shares owned by individuals account for 18.81%. As the largest shareholder in VERA with 14.66% of the stake, Fidelity Management & Research Co holds 4,055,804 shares worth 4,055,804. A second-largest stockholder of VERA, Citadel Advisors LLC, holds 1,991,473 shares, controlling over 7.20% of the firm’s shares. RA Capital Management LP is the third largest shareholder in VERA, holding 1,578,820 shares or 5.71% stake. With a 3.55% stake in VERA, the Fidelity Advisor Series VII – Bio is the largest stakeholder. A total of 980,468 shares are owned by the mutual fund manager. The Fidelity Select Port. – Biotechno, which owns about 2.82% of VERA stock, is the second-largest Mutual Fund holder. It holds 779,768 shares valued at 15.09 million. Fidelity Growth Company Fund holds 2.05% of the stake in VERA, owning 566,618 shares worth 10.96 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VERA since 7 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VERA analysts setting a high price target of $38.00 and a low target of $6.00, the average target price over the next 12 months is $19.17. Based on these targets, VERA could surge 322.69% to reach the target high and fall by -33.26% to reach the target low. Reaching the average price target will result in a growth of 113.24% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VERA will report FY 2022 earnings on 03/21/2024. Analysts have provided yearly estimates in a range of -$2.85 being high and -$3.37 being low. For VERA, this leads to a yearly average estimate of -$3.12. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Vera Therapeutics Inc. surprised analysts by -$0.21 when it reported -$0.91 EPS against a consensus estimate of -$0.70. The surprise factor in the prior quarter was $0.13. Based on analyst estimates, the high estimate for the next quarter is -$0.63 and the low estimate is -$1.02. The average estimate for the next quarter is thus -$0.86.

Summary of Insider Activity:

Insiders traded VERA stock several times over the past three months with 9 Buys and 9 Sells. In these transactions, 90,365 shares were bought while 26,200 shares were sold. The number of buy transactions has increased to 69 while that of sell transactions has risen to 66 over the past year. The total number of shares bought during that period was 1,381,216 while 271,104 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *